Takeda Pays $13.7M to Settle False Claims Act Violations of Paying Kickbacks to Physicians

Posted May 21, 2026

By the Constantine Cannon Whistleblower Team

Last Thursday (May 14), the Department of Justice (DOJ) announced that Japan-based Takeda Pharmaceuticals agreed to pay roughly $13.7 million to settle allegations it violated the False Claims Act and Anti-Kickback Statute by paying kickbacks to healthcare providers to induce prescriptions of Takeda’s Trintellix antidepressant medication.[1]

What Type of Kickbacks Did Takeda Allegedly Provide?

The Anti‑Kickback Statute bars providing or receiving financial inducements to induce referrals of goods or services covered by Medicare, Medicaid, and the other federal healthcare programs. The breadth of the prohibition is wide and encompasses virtually anything of value, including cash payments, travel and entertainment, below market value arrangements such as office space or equipment rentals, and free services or supplies. The statute is designed to ensure medical decision making is based on the patient’s best interests and not tainted by improper financial motivations.

According to the Government, Takeda paid improper remuneration to certain healthcare providers to induce them to prescribe Trintellix. The Government alleged the remuneration took the form of paid speaker opportunities and lavish meals. The Government further alleged that certain prescribers attended multiple “education” programs on the same topic, receiving meals and drinks from Takeda, but not receiving any educational benefit from attending duplicate programs. More of the specifics of Takeda’s conduct is further spelled out in the settlement agreement between DOJ and Takeda.[2]

Concealing kickbacks through speaker programs and honoraria, or through travel and entertainment associated with these programs, remains a common form of kickbacks in the healthcare space. In fact, two of the largest False Claims Act settlements last year — and included on our listing of the Top 10 False Claims Act Recoveries in 2025 — involved this precise type of misconduct.

In April 2025, California-based Gilead Sciences agreed to pay $202 million to settle False Claims Act charges of providing financial inducements to physicians to speak at or attend sham medical conferences to induce them to prescribe various Gilead HIV drugs. And in January 2025, Pfizer subsidiary Biohaven Pharmaceutical agreed to pay roughly $60 million to settle similar charges of providing healthcare professionals paid speaking opportunities and expensive meals to induce prescriptions of Biohaven’s migraine medication Nurtec. The Government further alleged the speaker programs provided no educational benefit and that certain programs were attended by individuals with no educational need to attend.

Is Going After Healthcare Kickbacks a DOJ Enforcement Priority?

As is clear from this continuous string of sizeable False Claims Act settlements, going after kickbacks remains a top DOJ enforcement priority. The Government reinforced this priority in announcing the recent Takeda settlement, with DOJ Civil Chief Brett Shumate stating simply and forcefully that his agency “is committed to vigorously pursuing violations of the False Claims Act arising from illegal kickbacks.” As he further elaborated, “such conduct can erode the trust that patients place in their healthcare providers and lead to higher drug costs for American taxpayers.”

US Attorney Eric Grant for the Eastern District California, where the Takeda matter was brought, put forth a similarly strong sentiment, underscoring how the settlement “demonstrates the continued commitment of my office to ensure that patients’ best interests remain paramount,” and that “prescribing decisions should not be influenced by drug companies’ payments or side perks made available to physicians.”

Acting HHS Deputy Inspector General for Investigations Scott Lampert added that his agency is equally committed to “investigate and hold accountable entities that attempt to disguise purported honoraria or other improper payments as legitimate compensation,” and that “decisions regarding patient care should never be influenced by extravagant meals or other inducements.”

What Role Can Whistleblowers Play in Reporting Illegal Kickbacks?

While there is no indication a whistleblower was involved in this matter, the majority of kickback cases are originated by whistleblowers under the qui tam provisions of the False Claims Act. These provisions allow private parties to bring lawsuits on behalf of the Government against those that defraud the Government. In return, successful whistleblowers can receive up to 30% of the Government’s recovery. Over the past thirty years, whistleblowers have received close to $10 billion in awards under the statute and have been responsible for originating the majority of False Claims Act cases.

The role of whistleblowers in reporting illegal kickbacks is especially important given the steps companies take to disguise them. As Constantine Cannon whistleblower partner Gordon Schnell previously commented in our post on last year’s Gilead kickback settlement: “With heavy Government enforcement in this area, healthcare companies are taking to ever-more sophisticated schemes to disguise their improper financial inducements. Without those on the inside with first-hand knowledge of these schemes, the Government has no easy way to identify and take action against them.”

Schnell points to his firm’s own experience in this area as a testament to the critical role whistleblowers play in supporting the Government with this top enforcement priority. “Most of the kickback arrangements our clients report would have been extremely difficult, if not impossible, for the Government to have identified on its own.” According to Schnell, “It is not just about following the flow of payments and other remuneration, but understanding their true underlying purpose and effect. That typically requires someone with a direct window into the misbehavior.”

Constantine Cannon Has Substantial Experience Representing False Claims Act Whistleblowers Reporting Kickback Violations

Constantine Cannon has substantial experience representing kickback whistleblowers under the False Claims Act. Most recently, we represented the whistleblower who helped DOJ secure a $34 million settlement against dialysis giant DaVita for allegedly paying physicians for referring patients to DaVita’s dialysis centers. He received an award of roughly 18.5% of the Government’s recovery.

If you would like to learn more about this matter, Constantine Cannon’s long list of False Claims Act successes, or what it means to be a whistleblower more broadly, please do not hesitate to contact us. We will connect you with an experienced member of the Constantine Cannon whistleblower team for a free and confidential consultation.